Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by restricted, repetitive, and inflexible patterns of behavior, interests, or activities and persistent deficits in social communication and reciprocal social interaction.
Many children with Autism exhibit impaired protein digestion, which may or may not manifest in self-restricted diets. The inability to digest protein affects the availability of essential amino acids in the body. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine.
According to the CDC, the prevalence of Autism has increased from 1 in 150 to 1 in 36 children over the past 20 years. In 2021, the Lancet Commission on the Future of Care and Clinical Research in Autism called for targeting treatment for ages of 0-6 when the neuroplasticity is greatest.
There is currently no approved drug on the market that treats the core symptoms of Autism.
At Curemark, we are working to change that. CM-AT, our lead drug candidate, is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids in children as young as 3. CM-AT has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA).
The Blüm™ Study enrolled children at over 30 sites around the US.
In the video above, Curemark founder and CEO, Dr. Joan Fallon gives a quick overview of the critical “brain/gut” connection in Autism, which our treatment aims to address.
